MarginsXMarginsX
Home › Markets › Health Care › BIVI

BioVie Inc. (BIVI)

BIVI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.08
-4.42% on the day
Market cap
$11.6M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBIVI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001580149
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
4.9 months
$7.7M cash at September 30, 2026
Share count, 1 year
+42.2%
2025-11-07 to 2026-11-05 · +2741.5% over 3 years
Going-concern doubt
Yes
10-Q filed November 6, 2026
Insider net buying, 12 months
$49K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These circumstances raise substantial doubt on the Company's ability to continue as a going concern."
10-Q 2026-11-06
Cash and burn$7.7M cash; operating cash flow -$4.7M a quarter.Report 2026-09-30
Shares outstanding10,724,724 (2026-11-05); 7,540,316 a year earlier; 37,742,695 three years earlier. 3y figure adjusted for splits (1-for-100 overall).Cover page 2026-11-05
Reverse splits, 3 years2; latest 1-for-10 on 2025-07-07Source 2025-07-07
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 4 424B5 takedowns, 2 at the marketLatest 2026-11-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEisnerAmper LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-08-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $49K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
Not filed-$5.6M-$2.9M$7.7MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q4 2026
2026-06-30
Not filed-$5.6M-$4.1M$9.0MNo debt tagsNeeds four quarters10-K 2026-08-13
Q3 2026
2026-03-31
Not filed-$5.3M-$7.4M$13.1MNo debt tagsNeeds four quarters10-Q 2026-05-11
Q2 2026
2025-12-31
Not filed-$6.1M-$4.4M$20.5MNo debt tagsNeeds four quarters10-Q 2026-05-11
Q1 2026
2025-09-30
Not filed-$5.1M-$3.0M$25.0MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q4 2025
2025-06-30
Not filed-$3.5M-$5.6M$17.5MNo debt tagsNeeds four quarters10-K 2026-08-13
Q3 2025
2025-03-31
Not filed-$2.8M-$1.3M$23.2MNo debt tagsNeeds four quarters10-Q 2026-05-11
Q2 2025
2024-12-31
Not filed-$7.1M-$8.6M$24.4MNo debt tagsNeeds four quarters10-Q 2026-05-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-05
Latest annual report
FORM 10-K FOR PERIOD ENDED JUNE 30, 2026
10-K2026-08-13
Latest quarterly / interim
FORM 10-Q FOR PERIOD ENDING SEPTEMBER 30, 2026
10-Q2026-11-06
Latest current report
CURRENT REPORT
8-K2026-11-10
Latest proxyDEF 14A2026-09-28

Source: SEC EDGAR submissions feed, 512 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.0%
1 month-5.8%
3 months-27.6%
Year to date-2.6%
1 year-24.2%
From 52-week high-50.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
BIVIWBioVie Inc. Warrant$0.2500

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DAREDare Bioscience Inc.$0.5842-11.13%$11.5M
LSTALisata Therapeutics Inc.$1.09-9.92%$11.8M
ASBPAspire-Lakewood Holdings Inc.$8.06-5.29%$11.3M
RADXRadiopharm Theranostics Limited$0.7676+1.00%$11.1M
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$1.44-10.56%$12.2M
PTNPalatin Technologies Inc.$6.13-1.69%$10.9M
OPTHOptimi Health Corp. Common Shares$2.15-4.44%$12.3M
HINDVyome Holdings Inc.$1.53-3.16%$10.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier